logo-loader
viewANGLE PLC

ANGLE says Queen Mary University patent could pave the way for a new use for its technology

The company's Parsortix device was used to harvest bone marrow cells called megakaryocytes

ANGLE PLC -

ANGLE PLC (LON:AGL OTCQX:ANPCY) said Queen Mary University of London has been awarded a European patent over a new and potentially ground-breaking method of cancer prognosis that uses the company’s liquid biopsy.

The AIM-listed med-tech firm has an option to take ownership of the procedure that is in place until June 2021 that allows it to expand the array of tests offered by its Parsortix device.

Queen Mary’s approach was to use the ANGLE technology to process blood so megakaryocyte cells could be counted.

There was a strong correlation between the number of these large bone marrow cells and patient survival, researchers found when assessing prostate cancer sufferers.

“We welcome the acceptance of this European patent and are excited by the potential for this entirely new way of assessing cancer through a simple blood test that has been enabled by ANGLE’s Parsortix system,” said chief executive Andrew Newland.

“We will now be investigating the possibility of adding megakaryocyte tests to our existing CTC [circulating tumour] tests as part of our sample-to-answer imaging solution under development.”

Parsortix is currently the only automated system that has demonstrated the capability of harvesting megakaryocytes. 

The company said patents in other countries are being sought for the new method of assessing for cancer.

Quick facts: ANGLE PLC

Price: 65.6 GBX

AIM:AGL
Market: AIM
Market Cap: £113.33 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ANGLE PLC submits its flagship Parsortix liquid biopsy diagnostic to the FDA

ANGLE PLC (LON:AGL) (OTCQX:ANPCY) CEO Andrew Newland tells Proactive the company has submitted its patent-protected, flagship Parsortix liquid biopsy diagnostic for clearance to the FDA.  Newland says this is a tremendous opportunity for ANGLE, as he says ANGLE is the first company to...

2 weeks, 2 days ago

2 min read